home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 07/16/21

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - China SXT Pharmaceuticals, Trinity Biotech leads healthcare gainers; FibroGen, Neptune Wellness Solutions among major losers

Gainers: China SXT Pharmaceuticals (SXTC) +37%, Trinity Biotech (TRIB) +11%, Moderna (MRNA) +9%, Aptevo Therapeutics (APVO) +9%, Apollo Medical (AMEH) +4%.Losers: FibroGen (FGEN) -45%, Neptune Wellness Solutions (NEPT) -20%, Atossa Therapeutic...
APVO - Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference

SEATTLE, WA / ACCESSWIRE / July 16, 2021 /  Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today&...

APVO - Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit

SEATTLE, WA / ACCESSWIRE / June 30, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announc...

APVO - Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies today announce...
APVO - APVO, SWBI, GSAT and NTEC among midday movers

Gainers: Lydall (LDL) +85%.Raven Industries (RAVN) +50%.Torchlight Energy Resources (TRCH) +45%.Alset EHome International (AEI) +39%.Globalstar (GSAT) +20%.ContextLogic (WISH) +19%.1847 Goedeker (GOED) +19%.Smith & Wesson Brands (SWBI) +17%.Anavex Life Sciences (AVXL) +17%....

APVO - Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Gainers: Virpax Pharmaceuticals (VRPX) +16%, Anavex Life Sciences AVXL +15%, MediciNova MNOV +14%, Aytu Biopharma (AYTU) +14%, Applied Molecular Transport (AMTI) +8%.Losers: Aptevo Therapeutics (APVO) -18%, Intec Pharma (NTEC) -16%, Conformis ...

APVO - Aptevo initiates expansion phase of APVO436 acute myeloid leukemia study

Aptevo Therapeutics (APVO) has initiated the expansion phase of the company's APVO436 study, in adult patients with acute myeloid leukemia ((AML)), with a multi-center, multi-arm trial using the active recommended dose.The active recommended dose was identified in the dose escalation phase ((...
APVO - Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia

Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ...

APVO - Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics ([[APVO]] +3.8%) shared positive data from a Phase 1 dose-escalation study designed to evaluate APVO436 in the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).The trial involving 46 patients with AML or myelodysplastic syndromes, met i...

APVO - Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / A...
Previous 10 Next 10